(New York, NY) -- Pfizer is projecting sales of its COVID-19 vaccine will surpass 30-billion dollars this year.
The New York-based pharmaceutical giant added its pill designed to fight the virus will generate more than 20-billion in sales. This is leading the company to believe it'll post an all-time high in revenue this year.
Despite that, Pfizer missed on revenue expectations in its latest quarterly earnings report. Analysts were looking for about 24-point-one billion dollars, but the number came in at 23-point-eight billion.